Biomerica (NASDAQ:BMRA) Director David Moatazedi Acquires 10,000 Shares

Biomerica, Inc. (NASDAQ:BMRA) Director David Moatazedi acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were bought at an average cost of $1.60 per share, for a total transaction of $16,000.00. Following the transaction, the director directly owned 40,625 shares of the company’s stock, valued at approximately $65,000. This trade represents a 32.65% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Biomerica Trading Up 24.3%

NASDAQ:BMRA opened at $2.10 on Friday. The firm has a market cap of $6.49 million, a PE ratio of -2.36 and a beta of 0.35. The stock has a fifty day moving average price of $1.66 and a 200 day moving average price of $1.99. Biomerica, Inc. has a 12-month low of $1.45 and a 12-month high of $3.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biomerica stock. BlackRock Inc. acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,636 shares of the company’s stock, valued at approximately $33,000. BlackRock Inc. owned about 0.60% of Biomerica as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.28% of the company’s stock.

Analyst Upgrades and Downgrades

BMRA has been the subject of several recent research reports. Citizens Jmp assumed coverage on Biomerica in a research note on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 price objective for the company. Weiss Ratings lowered shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 5th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell” and an average price target of $9.00.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.